Conmed Corp (CNMD) Stock Price & Analysis
Conmed Corp (CNMD) rose 6.99% to USD 36.9 as of June 10, 2026 at 02:23 UTC, according to Nexqual real-time market data.
CNMD last closed at USD 34.49; the session ranged USD 34.95–36.98 on volume of 428,072 shares. Market capitalization is $1.11B, with a 52-week range of USD 32.13–59.52 (NYQ). Source: Nexqual, June 10, 2026 at 02:23 UTC.
Key Statistics (as of June 10, 2026 at 02:23 UTC)
| Price | USD 36.9 |
|---|---|
| Change | ▲ 6.99% (up) |
| Previous Close | USD 34.49 |
| Open | USD 34.98 |
| Day Range | USD 34.95 – 36.98 |
| 52-Week Range | USD 32.13 – 59.52 |
| Volume | 428,072 shares |
| Market Cap | $1.11B |
| Exchange | NYQ |
Technical Analysis (CNMD)
Nexqual's technical model rates CNMD "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 02:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 53.35 (neutral) |
| vs SMA50 | Above (USD 36.45) |
| MACD | -0.47 (negative) |
Analyst Ratings (CNMD)
Wall Street analysts rate CNMD "Hold" based on 5 analysts, with a mean price target of USD 39.6 (range USD 39–40), per Nexqual as of June 10, 2026 at 02:23 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 39.6 |
| High Target | USD 40 |
| Low Target | USD 39 |
| Buy / Hold / Sell | 0 / 6 / 0 |
Earnings (CNMD)
| Next Earnings Date | 2026-04-29 |
|---|---|
| EPS Estimate | USD 1.1 |
| Revenue Estimate | $337.46M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.89 vs est 0.82 ▲ beat |
| 2025-12-31 | USD 1.43 vs est 1.32 ▲ beat |
| 2025-09-30 | USD 1.08 vs est 1.05 ▲ beat |
| 2025-06-30 | USD 1.15 vs est 1.12 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financials & Fundamentals (CNMD)
| Total Revenue | $1.37B |
|---|---|
| Revenue Growth (YoY) | -1.30% |
| Gross Margin | +54.06% |
| Operating Margin | +10.01% |
| Profit Margin | +4.00% |
| ROE | +5.50% |
| Debt / Equity | 84.59 |
| Current Ratio | 2.29 |
| Total Cash | $35.03M |
| Total Debt | $860.87M |
| Free Cash Flow | $125.87M |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Financial Health Score (CNMD)
Nexqual rates Conmed Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:23 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 54%, operating 10% |
| Balance Sheet | Mixed — $35M cash vs $861M debt |
| Cash Flow | Solid — FCF $126M, 9% margin |
| Efficiency | Mixed — ROE 5%, ROA 3.7% |
Ownership (CNMD)
| Insider Ownership | +0.43% |
|---|---|
| Institutional Ownership | +116.23% |
| Shares Outstanding | 30.11M |
| Float | 29.81M |
| Short % of Float | +9.24% |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
Leadership (CNMD)
Conmed Corp is led by Patrick J. Beyer (age 59), President, CEO & Director, per Nexqual as of June 10, 2026 at 02:23 UTC.
| President, CEO & Director | Patrick J. Beyer (age 59) |
|---|---|
| Executive Vice President of Strategy & Corporate Development | Peter K. Shagory (age 56) |
| Vice President of Compliance | Keith Seaton |
Major Backers & Investors (CNMD)
Notable institutional backers of Conmed Corp include Earnest Partners LLC, Fuller & Thaler Asset Management Inc., Bank of America Corporation, according to Nexqual as of June 10, 2026 at 02:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Earnest Partners LLC | 8.53% |
| Fuller & Thaler Asset Management Inc. | 5.45% |
| Bank of America Corporation | 4.66% |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 4.55% |
| SEI Investments Co | 3.34% |
| Cooke & Bieler LP | 3.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 24.74% |
| Vanguard Group | 18.63% |
| Dimensional Fund Advisors | 4.63% |
| State Street | 4.6% |
Source: Nexqual, June 10, 2026 at 02:23 UTC.
From Conmed Corp's Latest SEC 10-K Filing (filed 2026-02-17)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, our manufacturing processes and facilities, and those of third parties we contract with to provide regulated products and services, are subject to the FDA's Quality System Regulation ("QSR") and similar laws and regulations governing quality in other jurisdictions, and many of our products also are subject to industry-defined standards.
- We also pursue organic growth by focusing on our differentiated products.
- These products allow us to reach more surgeons and physicians and in turn also introduce other products in our portfolios. • Conduct Product Portfolio Review and Optimization.   We continuously review our product portfolio.
- The breadth of our product lines in our key product areas enables us to meet a wide range of customer requirements and preferences.  This has enhanced our ability to market our products to surgeons, hospitals, surgery centers, group purchasing organizations ("GPOs"), integrated delivery networks ("IDNs") and other customers, particularly as institutions seek to reduce costs and minimize the number of suppliers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OFIX | Orthofix Medical Inc. | USD 9.87 | ▼ 4.08% |
| ICUI | ICU Medical, Inc. | USD 142 | ▲ 3.95% |
| IART | Integra LifeSciences Holdings C | USD 17.9 | ▲ 5.36% |
| MMSI | Merit Medical Systems, Inc. | USD 67.51 | ▲ 4.7% |
| HAE | Haemonetics Corporation | USD 78.71 | ▲ 10.42% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:23 UTC. This page is informational and not investment advice.